{'fraction_non_alphanumeric': 0.016088060965283656, 'fraction_numerical': 0.021168501270110076, 'mean_word_length': 5.423913043478261, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Observation of the curative effect of two different doses somatostatin on 116 cases of esophagogastric variceal bleeding caused by cirrhosis

Objective: Investigate the clinical effect of two different doses somatostatin on esophagogastric variceal bleeding caused by cirrhosis. Method: The patients of 116 cases of esophagogastric variceal bleeding were divided into two groups randomly. The intravenous drip at 250 μg /h was performed on 59 cases in normal dose group constantly after slowly intravenous injections of 250 μg initial dose, while the intravenous drip at 200 μg /h was performed on 57 cases in small dose group as control group constantly after slowly intravenous injections of 200 μg initial dose. Observe the treatment effectiveness of the two groups, the incidence rate of rehaemorrhagia and the changing conditions of the side effect. Result: There is no statistical difference for treatment effectiveness, the incidence rate of rehaemorrhagia and the side effect between the somatostatin normal dose group and small dose control group(P>0.05). Conclusion: Small dose of somatostatin still has better curative effect on curing esophagogastric variceal bleeding.